Table 1.
Patient Characteristics: Frontline Treatment with R-CVP and R-CHOP
| Variable (N; %) |
R-CHOP N = 223 Hiddemann et al [5] |
R-CVP N = 162 Marcus et al [7] |
Total N = 385 |
P-value |
| Sex | M:88; 39.5% F: 135; 60.5% |
M: 88; 54.3% F: 74; 45.7% |
M: 176; 45.7% F: 209; 54.3% |
.004 |
| Age>60 | 82; 36.8% | 41; 25.3% | 123; 31.9% | .017 |
| ECOG>1 | 16; 7.2% | 4;2.5% | 20; 5.2% | .040 |
| B-symptoms | 80; 35.9% | 65; 40.1% | 145; 37.7% | .396 |
| Marrow involvement | 136; 61.0% | 103; 63.6% | 239; 62.1% | .605 |
| IPI> 2 | 42; 18.8% | 21; 13.0% | 63; 16.4% | .212 |
| Stage | I/II: 0; 0% III/IV: 223; 100% |
I/II: 2; 1.2% III/IV: 160; 98.8% |
I/II: 2; 0.5% III/IV: 383; 99.5% |
.342 |
| Elevetaed LDH | 51; 22.9% | 39; 24.1% | 90; 23.4% | .783 |